spacer
home > ict > autumn 2009 > cutting back
PUBLICATIONS
International Clinical Trials

Cutting Back

 

The golden age of the pharmaceutical industry in which pipelines were full and cash cows were ample seems to be fading away. Pipelines are getting thinner and patent time is quickly running out on existing revenue-generating products. To keep the pharmaceutical industry viable, innovative solutions are needed to cut back on the time and costs of clinical development.

The first cuts began about 15 years ago, when the industry realised that the consecutive phases of clinical development could be run in parallel. Twenty years ago, Phase I studies were generally run before Phase II studies, which in turn were completed before Phase III studies. Now, outside of the initial first-in-man and perhaps a Phase IIa dose-finding study, most Phase I studies are run alongside the Phase II and Phase III programme. But that was only the beginning. The pressure to compress clinical development time continues to grow, and managers are trying to find ways to shorten the time to get their products to market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After receiving her PhD in developmental neurobiology, Julia Forjanic Klapproth started her career as a Medical Writer in the pharmaceutical industry at Hoechst Marion Roussel (later Aventis) in 1997. Since then she has been President of the European Medical Writers Association (EMWA) twice (2001-2002, 2007-2009). Julia is also an experienced trainer of medical writers, regularly running workshops for EMWA and pharmaceutical companies around the world. In 2002, Julia co-founded Trilogy Writing & Consulting, a company specialised in providing medical writing. In addition to company management activities as Senior Partner and CEO, she continues to contribute her enthusiasm to client projects, writing a wide array of clinical documents. Numerous clients have depended on and appreciated her expertise in writing and coordinating study protocols, study reports, and CTD submission dossiers.
spacer
Julia Forjanic Klapproth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>

White Papers

Pandemic respiratory vaccine clinical trials: a departure from business as usual

ICON plc

Around the world, the “V” words are on everyone’s lips: Virus and Vaccines. In response to the urgent need for a vaccine for COVID-19, researchers are, at time of publication, running 500+ clinical trials (and counting) on a number of antivirals, antibodies and vaccines. Promising possibilities range from novel new drugs/vaccines, repurposing treatments currently indicated for HIV, Ebola and malaria, to monoclonal antibodies and immune serum.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement